PE20050020A1 - DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP - Google Patents

DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP

Info

Publication number
PE20050020A1
PE20050020A1 PE2004000364A PE2004000364A PE20050020A1 PE 20050020 A1 PE20050020 A1 PE 20050020A1 PE 2004000364 A PE2004000364 A PE 2004000364A PE 2004000364 A PE2004000364 A PE 2004000364A PE 20050020 A1 PE20050020 A1 PE 20050020A1
Authority
PE
Peru
Prior art keywords
oxo
pyridin
dihydro
carboxamide
imidazo
Prior art date
Application number
PE2004000364A
Other languages
English (en)
Inventor
Christopher S Burgey
Zhengwu J Deng
Daniel V Paone
Anthony W Shaw
Theresa M Williams
Diem N Nguyen
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20050020A1 publication Critical patent/PE20050020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE FORMULA I DONDE R1 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R2 ES H, ALQUILO C0-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R3 ES H, ALQUILO C1-C3 NO SUSTITUIDO O SUSTITUIDO, CN o CO2R4; R4 ES H, ALQUILO C1-C6, CICLOALQUILO C3-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[(3R,6S)-1-(2-METOXIETIL)-2-OXO-6-FENILAZEPAN-3-IL]-4-(2-OXO-2,3-DIHIDRO-1H-IMIDAZOL[4,5-b]PIRIDIN-1-IL)PIPERIDINA-1-CARBOXAMIDA; N-[(3R)-6-(4-HIDROXIFENIL)-2-OXOAZEPAN-3-IL]-4-(2-OXO-2,3-DIHIDRO-1H-IMIDAZOL[4,5-b]PIRIDIN-1-IL)PIPERIDINA-1-CARBOXAMIDA; N-{(3R,6S)-6-(2,3-DIFLUOROFENIL)-1-[2-(METILTIO)ETIL]-2-OXOAZEPAN-3-IL}-4-(2-OXO-2,3-DIHIDRO-1H-IMIDAZO[4,5-b]PIRIDIN-1-IL)PIPERIDINA-1-CARBOXAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA LA CUAL COMPRENDE UN TRANSPORTADOR INERTE Y UN COMPUESTO DERIVADO DE LA FORMULA I. ESTOS COMPUESTOS SON UTILES COMO LIGANDOS PARA RECEPTORES DEL PEPTIDO RELACIONADO CON EL GEN DE LA CALCITONINA (CGRP) EN PARTICULAR ANTAGONISTAS DE CGRP Y SON UTILES PARA EL TRATAMIENTO DEL DOLOR DE CABEZA, MIGRANA O CEFALEAS EN RACIMOS
PE2004000364A 2003-04-15 2004-04-12 DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP PE20050020A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46308903P 2003-04-15 2003-04-15
US51035203P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
PE20050020A1 true PE20050020A1 (es) 2005-02-18

Family

ID=33303112

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000364A PE20050020A1 (es) 2003-04-15 2004-04-12 DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP

Country Status (33)

Country Link
US (6) US6953790B2 (es)
EP (2) EP2039694B1 (es)
JP (1) JP3967766B2 (es)
KR (1) KR100769030B1 (es)
CN (1) CN100384843C (es)
AR (1) AR045887A1 (es)
AT (1) ATE413400T1 (es)
AU (1) AU2004230926B2 (es)
BR (1) BRPI0409601A (es)
CA (1) CA2522220C (es)
CL (1) CL2004000788A1 (es)
CO (1) CO5640130A2 (es)
CY (1) CY1108714T1 (es)
DE (1) DE602004017608D1 (es)
DK (1) DK1638969T3 (es)
EC (1) ECSP056097A (es)
ES (1) ES2314417T3 (es)
HK (1) HK1090922A1 (es)
HR (1) HRP20080666T3 (es)
IS (1) IS2759B (es)
JO (1) JO2355B1 (es)
MA (1) MA27728A1 (es)
MX (1) MXPA05011166A (es)
NO (1) NO327655B1 (es)
NZ (1) NZ543357A (es)
PE (1) PE20050020A1 (es)
PL (1) PL1638969T3 (es)
PT (1) PT1638969E (es)
RU (1) RU2308458C2 (es)
SI (1) SI1638969T1 (es)
TW (1) TWI314931B (es)
UA (1) UA82877C2 (es)
WO (2) WO2004092168A1 (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
NZ537315A (en) * 2002-06-05 2006-04-28 Bristol Myers Squibb Co Calcitonin gene related peptide receptor antagonists
ATE466860T1 (de) * 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
GB0310881D0 (en) * 2003-05-12 2003-06-18 Merck Sharp & Dohme Pharmaceutical formulation
EP1641423B1 (en) * 2003-06-26 2010-03-17 Merck Sharp & Dohme Corp. Benzodiazepine cgrp receptor antagonists
EP1641781B1 (en) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
CN101124217A (zh) * 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
JP2007526255A (ja) * 2004-02-23 2007-09-13 トラスティーズ オブ タフツ カレッジ コンフォメーション固定ペプチド模倣物阻害剤としてのラクタム類
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
EP1799672B1 (en) * 2004-10-07 2013-01-02 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CN101039718A (zh) * 2004-10-14 2007-09-19 默克公司 Cgrp受体拮抗剂
DE602005027230D1 (de) * 2004-10-22 2011-05-12 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
GB2423085C (en) * 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB2467060B (en) * 2005-02-11 2010-09-01 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
WO2006099268A2 (en) * 2005-03-14 2006-09-21 Merck & Co., Inc. Cgrp receptor antagonists
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP3045182B1 (en) 2005-11-14 2018-03-07 Teva Pharmaceuticals International GmbH Antagonist antibodies directed against calcitonin gene-related peptide for treating cluster headache
CN100371327C (zh) * 2005-11-17 2008-02-27 江苏工业学院 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法
US7851464B2 (en) * 2005-11-18 2010-12-14 Merck Sharp & Dohme Corp. Spirolactam aryl CGRP receptor antagonists
DE602007002182D1 (de) 2006-04-10 2009-10-08 Merck & Co Inc Verfahren zur herstellung von cgrp-antagonisten
DE602007001692D1 (de) * 2006-04-10 2009-09-03 Merck & Co Inc Herstellungsverfahren für ein zwischenprodukt eines caprolactam-cgrp-antagonisten
WO2007120592A1 (en) * 2006-04-10 2007-10-25 Merck & Co., Inc. Cgrp antagonist salt
CN101421267B (zh) * 2006-04-10 2011-10-19 默沙东公司 制备吡啶杂环cgrp拮抗剂中间体的方法
ATE517903T1 (de) * 2006-05-02 2011-08-15 Bristol Myers Squibb Co Verbindungen mit eingeschränkter konformation als cgrp rezeptor antagonisten.
US7470680B2 (en) * 2006-05-03 2008-12-30 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
BRPI0711352A2 (pt) * 2006-05-09 2011-09-27 Merck & Co Inc composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
WO2007146349A2 (en) * 2006-06-13 2007-12-21 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
MX2009001170A (es) * 2006-08-02 2009-05-21 Cytokinetics Inc Determinadas entidades quimicas, composiciones y metodos.
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2007293032A1 (en) * 2006-09-08 2008-03-13 Merck Sharp & Dohme Corp. Liquid pharmaceutical formulations for oral administration of a CGRP antagonist
NZ580887A (en) 2007-05-23 2012-03-30 Merck Sharp & Dohme Pyridyl piperidine orexin receptor antagonists
GB0712392D0 (en) * 2007-06-26 2007-08-01 Glaxo Group Ltd Novel compounds
US20090075977A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched mk0974
JP2011511792A (ja) * 2008-02-05 2011-04-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｃｇｒｐ受容体アンタゴニストのプロドラッグ
EP2254413A4 (en) * 2008-02-19 2011-10-26 Merck Sharp & Dohme IMIDAZOBENZAZEPIN-CGRP receptor antagonists
EP3441087A1 (en) 2008-03-04 2019-02-13 Teva Pharmaceuticals International GmbH Methods of treating chronic pain
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
AU2009267145A1 (en) * 2008-06-30 2010-01-07 Merck Sharp & Dohme Corp. Solid dosage formulations of telcagepant potassium
US8623863B2 (en) 2008-10-21 2014-01-07 Merck Sharp & Dohme Corp. Disubstituted azepan orexin receptor antagonists
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
EP2470207A1 (en) 2009-08-28 2012-07-04 Rinat Neuroscience Corporation Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
US8314117B2 (en) 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
TWI487706B (zh) 2010-11-12 2015-06-11 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2686324B1 (en) * 2011-03-18 2016-01-06 Merck Sharp & Dohme Corp. Piperidine carboxamide spirohydantoin cgrp receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
AR086515A1 (es) 2011-05-20 2013-12-18 Alderbio Holdings Llc Uso de anticuerpos o fragmentos de anticuerpos anti-cgrp o anti-cgrp-r para tratar o prevenir las formas cronicas y agudas de la diarrea
CA3079978A1 (en) 2011-05-20 2012-11-29 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
CN108014334B (zh) 2011-05-20 2021-11-30 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
AU2012281042B2 (en) 2011-07-13 2016-07-14 Cytokinetics, Inc. Combination ALS therapy
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
SI2820016T1 (sl) 2012-02-27 2017-11-30 Bristol-Myers Squibb Company N-(5s,6s,9r)-5-amino-6-(2,3-difluorofenil)-6,7,8,9-tetrahidro-5h- ciklohepta (b)piridin-9-il-4-(2-okso-2, 3-dihidro-1h-imidazo(4,5-b) piridin-1-il) piperidin-1-karboksilat, hemisulfatna sol
BR112014024203B1 (pt) 2012-03-29 2019-09-03 Bayer Ip Gmbh derivados de 5-aminopirimidina e sua utilização para o controle do crescimento de plantas indesejadas
CA2937315A1 (en) 2014-02-05 2015-08-13 Merck Sharp & Dohme Corp. Tablet formulation for cgrp-active compounds
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
UA123759C2 (uk) 2014-03-21 2021-06-02 Тева Фармасьютікалз Інтернешнл Гмбх Застосування моноклонального антитіла, яке інгібує шлях пов'язаного з геном кальциноніну пептиду (cgrp), для лікування або зниження частоти випадків мігренозного головного болю у суб'єкта
GB201417707D0 (en) 2014-10-07 2014-11-19 Viral Ltd Pharmaceutical compounds
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3366286A1 (en) 2017-02-22 2018-08-29 Johannes Keller Compounds for treating sepsis
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US11685729B2 (en) 2018-01-19 2023-06-27 Idorsia Pharmaceuticals Ltd. C5a receptor modulators
CN108892635A (zh) * 2018-09-07 2018-11-27 江苏工程职业技术学院 一种西沙必利关键中间体的制备方法
CA3123237A1 (en) 2019-01-08 2020-07-16 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-cgrp antibodies
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
MX2023007575A (es) 2020-12-22 2023-09-21 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CA3212151A1 (en) 2021-03-02 2022-09-09 Cgrp Diagnostics Gmbh Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1996035713A1 (en) 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
WO2000018764A1 (en) * 1998-09-30 2000-04-06 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
AU755425B2 (en) 1998-09-30 2002-12-12 Taisho Pharmaceutical Co., Ltd. Substituted isoxazolylthiophene compounds
NZ537315A (en) * 2002-06-05 2006-04-28 Bristol Myers Squibb Co Calcitonin gene related peptide receptor antagonists
ATE466860T1 (de) * 2003-04-15 2010-05-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten

Also Published As

Publication number Publication date
JP3967766B2 (ja) 2007-08-29
US7235545B2 (en) 2007-06-26
BRPI0409601A (pt) 2006-04-18
WO2004092168A1 (en) 2004-10-28
US20080280857A1 (en) 2008-11-13
MXPA05011166A (es) 2005-12-14
JO2355B1 (en) 2006-12-12
RU2308458C2 (ru) 2007-10-20
MA27728A1 (fr) 2006-01-02
EP2039694A1 (en) 2009-03-25
US7452903B2 (en) 2008-11-18
US20040229861A1 (en) 2004-11-18
EP2039694B1 (en) 2014-03-26
AU2004230926A1 (en) 2004-10-28
US20090192139A1 (en) 2009-07-30
IS8055A (is) 2005-09-29
EP1638969B1 (en) 2008-11-05
KR20050121734A (ko) 2005-12-27
TW200505903A (en) 2005-02-16
ATE413400T1 (de) 2008-11-15
WO2004092166A2 (en) 2004-10-28
JP2006523697A (ja) 2006-10-19
ECSP056097A (es) 2006-03-01
HK1090922A1 (en) 2007-01-05
US6953790B2 (en) 2005-10-11
RU2005135440A (ru) 2006-03-20
AR045887A1 (es) 2005-11-16
DK1638969T3 (da) 2009-01-26
CN100384843C (zh) 2008-04-30
NO20055375L (no) 2005-11-14
US7893052B2 (en) 2011-02-22
US7534784B2 (en) 2009-05-19
KR100769030B1 (ko) 2007-10-22
TWI314931B (en) 2009-09-21
CL2004000788A1 (es) 2005-02-25
UA82877C2 (en) 2008-05-26
NO327655B1 (no) 2009-09-07
PT1638969E (pt) 2009-01-16
US20050256098A1 (en) 2005-11-17
HRP20080666T3 (en) 2009-01-31
DE602004017608D1 (de) 2008-12-18
CO5640130A2 (es) 2006-05-31
US7772224B2 (en) 2010-08-10
AU2004230926B2 (en) 2008-07-17
IS2759B (is) 2011-10-15
US20070225272A1 (en) 2007-09-27
ES2314417T3 (es) 2009-03-16
CA2522220C (en) 2009-06-23
PL1638969T3 (pl) 2009-04-30
CY1108714T1 (el) 2014-04-09
CA2522220A1 (en) 2004-10-28
EP1638969A2 (en) 2006-03-29
SI1638969T1 (sl) 2009-02-28
CN1802376A (zh) 2006-07-12
NZ543357A (en) 2008-08-29
WO2004092166A3 (en) 2005-01-20
US20100298303A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
PE20050020A1 (es) DERIVADOS 4-(2-OXO-2,3-DIHIDRO-1-H-IMIDAZO[4,5-b]PIRIDIN-1-IL)-N-(2-OXO-AZEPAN-3-IL)PIPERIDINIL-1-CARBOXAMIDA SUSTITUIDOS COMO ANTAGONISTAS DEL RECEPTOR CGRP
RU2373209C2 (ru) Пирролотриазиновые соединения как ингибиторы киназ
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
PE20040583A1 (es) Nuevos derivados de benzimidazol
PE20060625A1 (es) Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20091095A1 (es) Moduladores de gamma secretasa
EA200501617A1 (ru) Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы
PE20110067A1 (es) Derivados de piperidina como inhibidores de renina
AR049696A1 (es) Derivados de indol
PE20060589A1 (es) FENILAMINOTIAZOLES SUSTITUIDOS COMO AGONISTAS DE ADENOSINA A1 Y A2b
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20090895A1 (es) Derivados de triazol como inhibidores de la jak quinasa
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
RU2015105561A (ru) Замещенные гетероазепиноны
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
MXPA05000081A (es) Quinolinas sustituidas antagonistas del receptor ccr5.
PE20070808A1 (es) COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20060599A1 (es) DERIVADOS PIRAZOLO-[3,4-d]-PIRIMIDINA COMO INHIBIDORES DE LA ACTIVIDAD DEL RECEPTOR CANNABINOIDE 1
PE20040592A1 (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion
CA2682329A1 (en) Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed